Agalsidase alfa

Details

Files

Generic Name:

Agalsidase alfa

Project Status:

Complete

Therapeutic Area:

Fabry Disease

Manufacturer:

Transkaryotic Therapies Inc.

Brand Name:

Replagal

Project Line:

Reimbursement Review

Project Number:

SR0006-000

Performance Metric:

N/A — Predated performance metrics

Submission Type:

Initial

Indications:

Fabry Disease

Recommendation Type:

Do not list

Final Recommendation:

November 24, 2004

Recommendation:

Not to list.

Files

Submission Status Report View PDF

Recommendation and Reasons View PDF

Last Updated : February 19, 2004